⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240948 | 0.81 | — | — | |
| SCHEMBL1292876 | 0.71 | — | — | |
| SCHEMBL4217 | 0.66 | — | — | |
| SCHEMBL2294957 | 0.64 | MAPT (0.33) | — | |
| Water SCHEMBL20742739 | 0.64 | MAPT (0.33) | — | |
| SCHEMBL71026 | 0.63 | — | — | |
| SCHEMBL569338 | 0.62 | — | — | |
| SCHEMBL12298859 | 0.62 | — | — | |
| SCHEMBL9583 | 0.62 | — | — | |
| SCHEMBL15618396 | 0.60 | PTPRC (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024099400-A1 | INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE (BEIJING) CO., LTD. (CN) | 2024-05-16 | — | — | WO | claimed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | claimed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4061966-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| EP-4062175-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | claimed |
| EP-3927324-A1 | PHARMACEUTICAL FORMULATIONS | Janssen Pharmaceutica NV (BE) | 2021-12-29 | — | — | EP | claimed |
| CN-113473971-A | Pharmaceutical formulations | 詹森药业有限公司 | 2021-10-01 | — | — | CN | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| CN-110191701-A | Composition is used in protein intensity reinforcing | 株式会社LG生活健康 | 2019-08-30 | — | — | CN | claimed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | claimed |
| WO-2019072237-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2019-04-18 | — | — | WO | claimed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | claimed |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2018-07-10 | — | — | US | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| EP-0929567-B1 | SOLID-PHASE PEPTIDE SYNTHESIS | ZEALAND PHARMA AS (DK) | 2005-03-02 | — | — | EP | claimed |